Suppression of the renin-angiotensin-aldosterone system is therefore a key strategy in the treatment of chronic cardiovascular and renal disease and is achieved by the administration of ACEi, ARBs, and mineralocorticoid receptor antagonists, alone or in combination. This evidence concerns the gene REN and cardiovascular disorder.